Bronchogen 20 mg

Bronchogen is a synthetic short peptide bioregulator developed within the Khavinson school of peptide research. It is classified as a tetrapeptide targeting bronchial and respiratory tract tissues, and is studied for its role in regulating cellular activity within the bronchial epithelium and mucosal layers of the airway. Its compact structure positions it among the low molecular weight regulatory peptides investigated for organ-specific signaling activity in respiratory research models.

Mechanistically, Bronchogen is examined for its influence on bronchial epithelial gene expression and chromatin-level transcriptional regulation. Experimental research models suggest that Khavinson-school tetrapeptides can interact with DNA-associated regulatory regions, modulate transcription factor activity, and influence cellular renewal processes in epithelial and mucosal tissues. These effects support its study as a signaling modulator rather than a direct pharmacological agent.

Research interest in Bronchogen has centered on bronchial epithelial gene expression, mucosal-barrier research, and respiratory-tract tissue renewal research models. Comparative investigations have explored its activity alongside other Khavinson-school bioregulators studied for organ-specific regulation, contributing to a broader understanding of peptide-mediated tissue homeostasis and age-associated functional decline in respiratory research environments (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

See also: Chonluten 20 mg, Cartalax 20 mg, and Cortagen 20 mg.

Specifications

• Purity: 99%
• Quantity: 20 mg
• Molecular Formula: C₁₈H₃₀N₄O₉
• Molecular Weight: 446.45 g/mol